NovaBay Pharmaceuticals, Inc. (NBY:NYSEMKT) closed at $1.95 on April 2, 2026, up 22.64% on the day. The stock trades 98.0% below its 52-week high of $99.75 and 75.7% above its 52-week low of $1.11. NovaBay Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, NBY closed higher on 53 days (21%). Its best day was January 9, 2026 (+102.54%) and its worst was January 20, 2026 (-55.99%). The stock moved 10% or more in a single session 38 times.
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Find more stocks like NBY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.